[1] 中国抗癌协会肿瘤标志专业委员会遗传性肿瘤标志物协作组等. "同源重组修复缺陷临床检测与应用专家共识(2021版)." 中国癌症防治杂志 2021年13卷4期, 329-338页 (2021).
[2] 中华医学会妇科肿瘤学分会. 卵巢癌PARP抑制剂临床应用指南[J]. 2020.
[3] Patrick G Pilié, et al. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol. 2019 Feb;16(2):81-104.
[4] 二代测序临床报告解读肿瘤学专家组, 张绪超. 肿瘤二代测序临床报告解读共识[J]. 循证医学, 2022, 22(2):15.
[5] Fujiwara K , Harter P , Leary A , et al. Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev[J]. Annals of Oncology, 2019, 30:ix191-ix192.
[6] 温灏. PARP抑制剂不良反应管理的中国专家共识(2021年版).
[7] 中国抗癌协会妇科肿瘤专业委员会, 中华医学会病理学分会. 上皮性卵巢癌PARP抑制剂相关生物标志物检测的中国专家共识[J]. 中国癌症杂志, 2020, 30(10):841-848.
[8] Ovarian Cancer Including Fallopian Tube Cancer and Primary Peritoneal Cancer,Version 1.2022,NCCN Clinical Practice Guidelines in Oncology.
[9] Prostate Cancer, Version 4.2022, NCCN Clinical Practice Guidelines in Oncology.
[10] Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology.
[11] 中国抗癌协会泌尿男生殖系肿瘤专业委员会, 中国临床肿瘤学会前列腺癌专家委员会. 中国前列腺癌患者基因检测专家共识(2020年版).
[12] Pancreatic Adenocarcinoma, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology.